Multiple myeloma with IGH-FGFR3 rearrangement progressing as testicular plasmacytoma during carfilzomib treatment

Ann Hematol. 2019 Oct;98(10):2463-2465. doi: 10.1007/s00277-019-03743-6. Epub 2019 Jun 25.

Affiliations

¹ Department of Hematology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
² Department of Hematology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. dmaruyam@ncc.go.jp.
³ Department of Pathology and Clinical Laboratory, National Cancer Center Hospital, Tokyo, Japan.
⁴ Department of Urology, National Cancer Center Hospital, Tokyo, Japan.

PMID: 31240468
DOI: 10.1007/s00277-019-03743-6

No abstract available

Publication types

Letter

MeSH terms

Aged
Autografts
Humans
Immunoglobulin Heavy Chains* / genetics
Immunoglobulin Heavy Chains* / metabolism
Male
Multiple Myeloma* / genetics
Multiple Myeloma* / metabolism
Multiple Myeloma* / pathology
Multiple Myeloma* / therapy
Neoplasms, Second Primary* / genetics
Neoplasms, Second Primary* / metabolism
Neoplasms, Second Primary* / pathology
Neoplasms, Second Primary* / therapy
Oligopeptides / administration & dosage*
Oncogene Proteins, Fusion* / genetics
Oncogene Proteins, Fusion* / metabolism
Plasmacytoma* / genetics
Plasmacytoma* / metabolism
Plasmacytoma* / pathology
Plasmacytoma* / therapy
Receptor, Fibroblast Growth Factor, Type 3* / genetics
Receptor, Fibroblast Growth Factor, Type 3* / metabolism
Stem Cell Transplantation*
Testicular Neoplasms* / genetics
Testicular Neoplasms* / metabolism
Testicular Neoplasms* / pathology
Testicular Neoplasms* / therapy

Substances

Immunoglobulin Heavy Chains
Oligopeptides
Oncogene Proteins, Fusion
carfilzomib
FGFR3 protein, human
Receptor, Fibroblast Growth Factor, Type 3